Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 6/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420018 | 1.00 | MAT2A (0.40) | MAT2AGRM1MAOBPI4KB | |
| SCHEMBL30420252 | 0.86 | MAT2A (0.42) | MAT2AGRM1MAOB | |
| SCHEMBL26485221 | 0.86 | MAT2A (0.42) | MAT2AGRM1MAOB | |
| SCHEMBL26091386 | 0.86 | MAT2A (0.35) | MAT2AGRM1 | |
| SCHEMBL30420280 | 0.86 | MAT2A (0.35) | MAT2AGRM1 | |
| SCHEMBL26485128 | 0.84 | MAT2A (0.50) | MAT2AGRM1MAOB | |
| SCHEMBL30418873 | 0.84 | MAT2A (0.50) | MAT2AGRM1MAOB | |
| SCHEMBL26485224 | 0.83 | MAT2A (0.36) | MAT2A | |
| SCHEMBL30420259 | 0.83 | MAT2A (0.36) | MAT2A | |
| SCHEMBL26487645 | 0.79 | MAT2A (0.35) | MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-06-04 | — | — | US | disclosed |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2023066283-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | MAT2A, MAT2B, MAT1A | MAT2A 1/4885GRM1 323/4885MAOB 132/4885 |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | MAT2A, MAT2B, MAT1A | MAT2A 1/4885GRM1 323/4885MAOB 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.